Startup Roundup
Israel’s Chiasma raises $70M to treat growth hormone disorders
Biopharmaceutical developer, Chiasma, has announced the closing of a $70 million Series E financing round. The company is developing octreotide capsules, its lead product for the orphan condition acromegaly (a disorder stemming from an excess of growth hormones). Chiasma will use the funds to prepare for the commercial launch of its treatment. The company is headquartered in Jerusalem and Newton, Massachusetts. Learn more.